Lisata Therapeutics, Inc. (LSTA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Lisata Therapeutics, Inc. (LSTA) closed at USD 1.02 on 2026-10-14, a change of -63.3 % over the past year, with a market capitalization of USD 11.56M.

Lisata Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lisata Therapeutics, Inc. key figures

Previous close

USD 1.02 (2026-10-14)

1-year change

-63.3 %

Market cap

USD 11.56M

Enterprise value

USD -1.06M

P/E ratio (trailing)

-0.67

P/E ratio (forward)

-0.92

EPS (trailing)

-1.61

EPS (forward)

-1.16

PEG ratio

118.40

Price to book

1.18

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.14

Employees

21

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lisata Therapeutics, Inc. and compare it with other stocks.